Chai Jian-Guo, Ratnasothy Kulachelvy, Bucy R Pat, Noelle Randolph J, Lechler Robert, Lombardi Giovanna
MRC Centre for Transplantation, King's College London, London, UK.
Therapeutic Immunology Group, Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Eur J Immunol. 2015 Jul;45(7):2017-27. doi: 10.1002/eji.201545455. Epub 2015 May 20.
Although donor-specific transfusion (DST) plus CD154 blockade represents a robust protocol for inducing transplantation tolerance, the underlying mechanisms are incompletely understood. In a murine T-cell adoptive transfer model, we have visualized alloantigen-specific, TCR-transgenic for H2-A(b) /H2-K(d) 54-68 epitope (TCR75) CD4(+) T cells with indirect allospecificity during the course of tolerance induction. Three main observations were made. First, although the majority of TCR75 CD4(+) T cells were deleted following DST plus CD154 blockade, the surviving TCR75 CD4(+) T cells were capable of making IL-2, upregulating CD44, and undergoing cell division, suggesting that they were functionally active. Indeed, residual TCR75 CD4(+) T cells reisolated from the primary recipients given DST plus CD154 blockade were fully capable of rejecting allografts upon secondary transfer. Second, in tolerant mice, TCR75 CD4(+) T cells were not induced to express Foxp3 in the graft-draining lymph node. TCR75 CD4(+) T cells were also absent in accepted graft tissues in which endogenous Treg cells were enriched. Finally, DST plus CD154 blockade resulted in an abortive expansion of TCR75 CD4(+) T cells, a process that required the presence of endogenous Treg cells. Collectively, surviving TCR75 CD4(+) T cells are immunocompetent but kept in check by an endogenous immunosuppressive network induced by DST plus CD154 blockade.
尽管供体特异性输血(DST)加CD154阻断是诱导移植耐受的有效方案,但其潜在机制尚未完全明确。在小鼠T细胞过继转移模型中,我们观察到在耐受诱导过程中,具有间接同种特异性、针对H2-A(b)/H2-K(d) 54-68表位(TCR75)的同种抗原特异性TCR转基因CD4(+) T细胞。我们有三个主要发现。第一,尽管大多数TCR75 CD4(+) T细胞在DST加CD154阻断后被清除,但存活的TCR75 CD4(+) T细胞能够产生白细胞介素-2、上调CD44并进行细胞分裂,这表明它们具有功能活性。事实上,从接受DST加CD154阻断的初次受体中重新分离出的残余TCR75 CD4(+) T细胞在二次转移时完全能够排斥同种异体移植物。第二,在耐受小鼠中,TCR75 CD4(+) T细胞在移植引流淋巴结中未被诱导表达Foxp3。在富含内源性调节性T细胞(Treg)的已接受移植组织中也不存在TCR75 CD4(+) T细胞。最后,DST加CD154阻断导致TCR75 CD4(+) T细胞的流产性扩增,这一过程需要内源性Treg细胞的存在。总体而言,存活的TCR75 CD4(+) T细胞具有免疫活性,但受到DST加CD154阻断诱导的内源性免疫抑制网络的控制。